Development of therapy of Alzheimers disease with iPS cell-derivedmacrophages

The purpose of this study is to generate macrophages with acapacity to degrade or remove amyloid-·protein，which is known to be the causative agentof Alzheimer‘s disease.Before this project，we had established a technology to generate functionalphagocytes(Macrophages)from mouse and human iPS cells。In the current study，wegenerated macrophages expressing Fc-receptor-fused form of single chain antibody specificto amyloid-·.In addition，we made macrophages expressing neprilysin，a protease reportedto be highly potent in degradation of amyloid-·.We administered the genetically modifiediPS cell-derived macrophages into model mice of Alzheimer‘s disease，and evaluate whetherthey could reduce the level of amyloid-·in vivo.

The purpose of this study is to generate macrophages with acapacity to degrade or remove amyloid-・protein, which is known to be the causative agentof Alzheimer ’ s disease.Before this project, we had established a technology to generate functionalphagocytes (macrophages) from mouse and human iPS cells. In the current study , wegenerated macrophages expressing Fc-receptor-fused form of single chain antibody specificto amyloid-・. In addition, we made macrophages expressing neprilysin, a protease reportedto be highly potent in degradation of amyloid-・. We administered the genetically modifiediPS cell-derived macrophages into model mice of Alzheimer ’ s disease, and evaluate whetherthey could reduce the level of amyloid-・in vivo.